ZFIN ID: ZDB-PUB-200119-1
Sphingosine 1-Phosphate Receptor 2 Induces Otoprotective Responses to Cisplatin Treatment
Wang, W., Shanmugam, M.K., Xiang, P., Yam, T.Y.A., Kumar, V., Chew, W.S., Chang, J.K., Ali, M.Z.B., Reolo, M.J.Y., Peh, Y.X., Karim, S.N.B.A., Tan, A.Y.Y., Sanda, T., Sethi, G., Herr, D.R.
Date: 2020
Source: Cancers   12(1): (Journal)
Registered Authors: Sanda, Takaomi
Keywords: CYM-5478, acoustic startle response, auditory brainstem response, cisplatin, cochlea, hearing loss, ototoxicity, reactive oxygen species, sphingosine 1-phosphate
MeSH Terms: none
PubMed: 31952197 Full text @ Cancers
Ototoxicity is a major adverse effect of platinum-based chemotherapeutics and currently, there remains a lack of United States Food and Drug Administration-approved therapies to prevent or treat this problem. In our study, we examined the role of the sphingosine 1-phosphate receptor 2 (S1P2) in attenuating cisplatin-induced ototoxicity in several different animal models and cell lines. We found that ototoxicity in S1P2 knockout mice is dependent on reactive oxygen species (ROS) production and that S1P2 receptor activation with a specific agonist, CYM-5478, significantly attenuates cisplatin-induced defects, including hair cell degeneration in zebrafish and prolonged auditory brainstem response latency in rats. We also evaluated the cytoprotective effect of CYM-5478 across different cell lines and showed that CYM-5478 protects neural-derived cell lines but not breast cancer cells against cisplatin toxicity. We show that this selective protection of CYM-5478 is due to its differential effects on key regulators of apoptosis between neural cells and breast cancer cells. Overall, our study suggests that targeting the S1P2 receptor represents a promising therapeutic approach for the treatment of cisplatin-induced ototoxicity in cancer patients.